Patents by Inventor Andrew R. Crow

Andrew R. Crow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating autoimmune diseases and compositions therefor
    Patent number: 8597636
    Abstract: A method of cell-based therapy for treating an autoimmune disease is disclosed. The method is directed at stimulating leukocytes and/or dendritic cells to interrupt autoimmunity in a host. The method provides a Fc? receptor-specific complex or a complex which results in the co-crosslinking of Fc?-chains for treating the leukocytes and/or dendritic cells which are in turn used to elicit an autoimmune interruption response in a subject with an autoimmune disease. The Fc? receptor-specific complex and/or complex which results in the co-crosslinking of Fc?-chains is used to treat a biological sample comprising leukocytes and/or dendritic cells from a patient, and upon reintroducing said biological sample to the patient, the pre-treated dendritic cells illicit an autoimmune interruption response in vivo.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: December 3, 2013
    Assignee: Canadian Blood Services
    Inventors: Alan H. Lazarus, Vinayakumar Siragam, Davor Brinc, John Freedman, Andrew R. Crow, Seng Song
  • Method for Treating Autoimmune Diseases With Antibodies
    Publication number: 20080050391
    Abstract: A method for treating autoimmune diseases in a mammal which method comprises administering to the mammal an effective amount of at least one antibody specific for a soluble antigen is provided. Furthermore, a novel mechanism of action has been established in accordance with the present invention for antibody-based treatment regimes for autoimmune disease, including but not limited to anti-CD44 and soluble antigen specific antibody treatment regimes.
    Type: Application
    Filed: March 30, 2005
    Publication date: February 28, 2008
    Inventors: Alan H. Lazarus, Seng Song, Andrew R. Crow, Vinayakumar Siragam, Davor Brinc, John Freedman
  • Methods of inhibiting platelet anti-HLA alloimmune antibody responses with soluble 18 KDa CD40L
    Patent number: 7087573
    Abstract: The invention relates to a method for inhibiting an in vivo alloimmune response, and to the use of a soluble recombinant human CD40L protein containing the active binding site with CD40. In particular, a soluble 18 KDa recombinant CD40L is used to inhibit an in vivo alloimmune response.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: August 8, 2006
    Assignee: Canadian Blood Services
    Inventors: Alan H. Lazarus, Andrew R. Crow, John Freedman
  • Method for preventing and inhibiting human HLA alloimmune response to platelet transfusion
    Patent number: 6749852
    Abstract: The present invention relates to a method for preventing HLA alloimmune response to platelet transfusion. The method comprises the step of presensitizing platelets with at least one monoclonal HLA antibody. The platelets if administered to a patient prevent an HLA alloimmune response from said patient.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: June 15, 2004
    Assignee: Canadian Blood Services
    Inventors: Alan H. Lazarus, John Freedman, Andrew R. Crow
  • Method for treating thrombocytopenia with monoclonal ivig
    Publication number: 20040047862
    Abstract: The present invention relates to a method and composition utilizing monoclonal intravenous immunoglobulin (mIVIG) for increasing platelet cell counts in thrombocytopenia. The method and composition are suitable for treatments of patients suffering from medical conditions, such as idiopathlic thrombocytopenic purpura (ITP), which result in low platelet cell numbers.
    Type: Application
    Filed: August 22, 2003
    Publication date: March 11, 2004
    Inventors: Alan H. Lazarus, John Freedman, Seng Song, Andrew R. Crow